Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study

Key Findings:  The synthetic pharmaceutical cannabinoid or THC analogue i.e. nabilone significantly reduces levodopa-induced dyskinesia in patients with Parkinson's Disease.

Type of Study:  Double Blind Human Trial

Study Sample Size:  7

Study Result:  Positive

Cannabinoids Studied:  Pharma THC

Phytocannabinoid Source:  Not Applicable

Chemotype:  Chemotype I

Form of Administration:  Ingestion

Sub-Ratio: 1:0

Study Location(s):  United Kingdom

Year of Pub:  2001

Link to study